The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis
Preventive Medicine Center Hospital Israelita Albert Einstein, Sao Paulo, Brazil. Annals of Medicine
(Impact Factor: 3.89).
05/2011; 43(6):487-94. DOI: 10.3109/07853890.2011.554428
INTRODUCTION. Hepatic steatosis due to non-alcoholic fatty liver disease is associated with obesity, dyslipidemia, insulin resistance, and type 2 diabetes. The Finnish Diabetes Risk Score (FINDRISC) is a prognostic screening tool to detect people at risk for type 2 diabetes without the use of any blood test. The objective of this study was to evaluate whether FINDRISC can also be used to screen for the presence of hepatic steatosis. PATIENTS AND METHODS. Steatosis was determined by ultrasound. The study sample consisted of 821 non-diabetic subjects without previous hepatic disease; 81% were men (mean age 45 ± 9 years) and 19% women (mean age 41 ± 10 years). RESULTS. Steatosis was present in 44% of men and 10% of women. The odds ratio for one unit increase in the FINDRISC associated with the risk of steatosis was 1.30 (95% CI 1.25-1.35), similar for men and women. The area under the receiver operating characteristics curve for steatosis was 0.80 (95% CI 0.77-0.83); 0.80 in men (95% CI 0.77-0.83) and 0.83 (95% CI 0.73-0.93) in women. CONCLUSIONS. Our data suggest that the FINDRISC could be a useful primary screening tool for the presence of steatosis.
Available from: PubMed Central
- "Several previous studies have shown that FINDRISC was related to type 2 diabetes, the metabolic syndrome, insulin resistance , , . In a recent cross-sectional study including 821 Brazil non-diabetic subjects without previous hepatic disease, it was found that the FINDRISC could be a useful primary screening tool for the presence of steatosis . In that study the ROC curve for the undiagnosed prevalent diabetes was 0.80, 0.80 in men and 0.83 in women, which was consistent with the present findings. "
[Show abstract] [Hide abstract]
ABSTRACT: Hepatic steatosis has been related to insulin resistance and increased diabetes risk. We assessed whether combination of diabetes risk factors, evaluated by the Finnish Diabetes Risk Score, was associated with risk of hepatic steatosis in an apparently healthy Chinese population.
The study samples were from a community-based health examination survey in central China. In total 1,780 men and women (18-64 y) were included in the final analyses. Hepatic steatosis was diagnosed by ultrasonography. We created combination of diabetes risk factors score on basis of age, Body Mass Index, waist circumference, physical activity at least 4 h a week, daily consumption of fruits, berries or vegetables, history of antihypertensive drug treatment, history of high blood glucose. The total risk score is a simple sum of the individual weights, and values range from 0 to 20.
Hepatic steatosis was present 18% in the total population. In multivariate models, the odds ratios of hepatic steatosis were 1.20 (95%CI 1.15-1.25) in men and 1.25 (95%CI 1.14-1.37) in women by each unit increase in the combination of diabetes risk factors score, after adjustment for blood pressure, liver enzymes, plasma lipids, and fasting glucose. The area under the receiver operating characteristic curve for hepatic steatosis was 0.78 (95%CI 0.76-0.80), 0.76 in men (95%CI 0.74-0.78) and 0.83 (95%CI 0.79-0.87) in women.
Our data suggest that combination of major diabetes risk factors was significantly related to risk of hepatic steatosis in Chinese adults.
PLoS ONE 03/2014; 9(3):e90101. DOI:10.1371/journal.pone.0090101 · 3.23 Impact Factor
Annals of Medicine 05/2011; 43(6):413-7. DOI:10.3109/07853890.2011.579152 · 3.89 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) has emerged as a significant public health problem. Besides the liver, NAFLD is also associated with increased cardiovascular and overall morbidity and mortality. NAFLD warrants intensive research, because no treatment has been established as yet. This may be partly attributed to the fact that the majority of the relative clinical trials have a monotherapeutic direction. However, the multifactorial pathogenesis of NAFLD may probably direct clinical trials to a combined therapeutic approach. The aim of this review is to provide a description of the multifactorial pathogenesis of NAFLD and type II diabetes mellitus-NAFLD interplay, and to summarize the therapeutic trials focusing on the combined NAFLD treatment, providing a link between the multiple-hit pathogenesis and the multimodal treatment of NAFLD patients. A diabetes-like therapeutic approach for NAFLD is finally proposed.
Journal of clinical gastroenterology 04/2012; 46(4):272-84. DOI:10.1097/MCG.0b013e31824587e0 · 3.50 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.